Investors take note of Opthea’s potential

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more

MiSight continues to slow myopia

Five year results from the world’s longest-running clinical trial of paediatric contact lens wear has shown CooperVision’s MiSight 1 Day lens continues to slow myopia in children, even at older ages. Read more

New approach needed for AMD research

A working group assembled by the US National Advisory Eye Council (NAEC) has called for a change in strategy among researchers investigating potential cures for atrophic age-related macular degeneration (AMD). Read more

Sight For All silent on Oscar Wylee charity claims

Australian eye health charity Sight For All has gone silent on its dealings with the optical chain Oscar Wylee, following revelations that several of the retailer’s philanthropic marketing claims had been called into question and refuted.

Read more